Followers | 31 |
Posts | 3792 |
Boards Moderated | 1 |
Alias Born | 09/24/2012 |
Friday, February 12, 2016 5:04:10 PM
I followed your post and decided to post the info here for all to see below.
Glta Stockholders!!!
Note That company's website shows up to date (website)copyright 2016...
******************************************************************
Anti-Human Phosphatidylserine Therapeutic Antibody (Bavituximab) from Creative Biolabs
Recombinant monoclonal antibody to phosphatidylserine. Bavituximab is a chimeric monoclonal antibody designed for the treatment of cancers and viral infections
Product Details
ItemAnti-Human Phosphatidylserine Therapeutic Antibody (Bavituximab)
Company Info
CompanyCreative Biolabs
Price Supplier PageView Company Product Page
Catalog NumberTAB-175
Quantity1mg
ApplicationsFuncS, IF, Neut, ELISA, FC, IP, ICC
Conjugate/Tag/LabelUnconjugated
ReactivityHuman
Antigenphosphatidylserine
HostMouse
Source/Expression SystemCHO
TemperatureStore the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples
Bavituximab (TAB-175)
Share:
Recombinant monoclonal antibody to phosphatidylserine. Bavituximab is a chimeric monoclonal antibody designed for the treatment of cancers and viral infections.
Datasheet
Specifications
ImmunogenLiposomes containing 70% phosphatidylserine and 30% phosphatidylglycerol.
Host AnimalMouse
DerivationChimeric (mouse/human)
TypeIgG1 - kappa
SpecificityTested positive against native human antigen.
Species ReactivityHuman
ApplicationsSuitable for use in FuncS, IF, Neut, ELISA, FC, IP, ICC and most other immunological methods.
CAS NO.648904-28-3
Generic NameBavituximab
Biological Half-Life30 hrs
UNIIQ16CT95N25
M.W.145.3 kDa
Related DiseaseInfluenza
Target
Alternative NamesBavituximab;648904-28-3;ch3G4;PGN401;Phosphatidylserine;PS;Ptd-L-Ser
For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
See other products for "phosphatidylserine"
Recombinant Anti-Human phosphatidylserine VHH Single Domain Antibody ( NAB-1906-VHH )
>> MORE
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
45-1 Ramsey Road, Shirley, NY 11967, USA Tel: 1-631-871-5806 Fax: 1-631-207-8356 Email: info@creative-biolabs.com
Terms of Service-Privacy Policy © 2007 - 2016 Creative-Biolabs All Rights Reserved
Recent CDMO News
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/19/2023 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:34:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:33:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:32:11 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM